{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:25:16Z","timestamp":1774459516650,"version":"3.50.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82403334"],"award-info":[{"award-number":["No.82403334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hubei Provincial Natural Science Foundation of China","award":["No.2024AFB214"],"award-info":[{"award-number":["No.2024AFB214"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["No.2024M752491"],"award-info":[{"award-number":["No.2024M752491"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University","award":["ZNJC202416"],"award-info":[{"award-number":["ZNJC202416"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11084-z","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:19:24Z","timestamp":1759994364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Palmitoylation modulates antitumor immunity"],"prefix":"10.1007","volume":"52","author":[{"given":"Feng","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Long","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Di","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"3","key":"11084_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"11084_CR2","doi-asserted-by":"crossref","unstructured":"Kimberly D, Miller L, Nogueira T, Devasia et al Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin, 72(5)","DOI":"10.3322\/caac.21731"},{"key":"11084_CR3","doi-asserted-by":"crossref","unstructured":"Roger Stupp S, Taillibert A, Kanner et al Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. (2017) . JAMA, 318(23)","DOI":"10.1001\/jama.2017.18718"},{"key":"11084_CR4","doi-asserted-by":"publisher","unstructured":"Zhang M, Nie YFL et al (2022) Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced Non-small cell lung cancer and preexisting interstitial lung diseases: A systematic review and Meta-analysis. Chest 161(6). https:\/\/doi.org\/10.1016\/j.chest.2021.12.656","DOI":"10.1016\/j.chest.2021.12.656"},{"key":"11084_CR5","doi-asserted-by":"publisher","unstructured":"Matteo S, Carlino J, Larkin GVL (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304). https:\/\/doi.org\/10.1016\/s0140-6736(21)01206-x","DOI":"10.1016\/s0140-6736(21)01206-x"},{"issue":"4","key":"11084_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.cd-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S (2021) The next decade of immune checkpoint therapy. Cancer Discov 11(4):838\u2013857. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1680","journal-title":"Cancer Discov"},{"issue":"2","key":"11084_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"3","key":"11084_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW et al (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76(3):359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"key":"11084_CR9","doi-asserted-by":"publisher","unstructured":"Ausejo-Mauleon I, Labiano S, de la Nava D et al (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell, 41(11): 1911\u20131926.e1918. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.001","DOI":"10.1016\/j.ccell.2023.09.001"},{"key":"11084_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L (2022) Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol 40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"11084_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41580-024-00700-8","volume":"25","author":"S Mesquita","year":"2024","unstructured":"Mesquita S, Abrami F, Linder L ME, et al (2024) Mechanisms and functions of protein S-acylation. Nat Rev Mol Cell Biol 25(6):488\u2013509. https:\/\/doi.org\/10.1038\/s41580-024-00700-8","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"11084_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrm2084","volume":"8","author":"ME Linder","year":"2007","unstructured":"Linder ME, Deschenes RJ (2007) Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol 8(1):74\u201384. https:\/\/doi.org\/10.1038\/nrm2084","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"11084_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.devcel.2020.06.036","volume":"54","author":"G Figlia","year":"2020","unstructured":"Figlia G, Willnow P, Teleman AA (2020) Metabolites regulate cell signaling and growth via covalent modification of proteins. Dev Cell 54(2):156\u2013170. https:\/\/doi.org\/10.1016\/j.devcel.2020.06.036","journal-title":"Dev Cell"},{"issue":"101","key":"11084_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp7302","volume":"9","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Ren C, Xiao R (2024) Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol 9(101):eadp7302. https:\/\/doi.org\/10.1126\/sciimmunol.adp7302","journal-title":"Sci Immunol"},{"key":"11084_CR15","doi-asserted-by":"publisher","unstructured":"Han Yao J, Lan C, Li et al (2019) Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng 3(4). https:\/\/doi.org\/10.1038\/s41551-019-0375-6","DOI":"10.1038\/s41551-019-0375-6"},{"issue":"4","key":"11084_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C et al (2019) Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng 3(4):306\u2013317. https:\/\/doi.org\/10.1038\/s41551-019-0375-6","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"11084_CR17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C (2022) The role of lipids in cancer progression and metastasis. Cell Metab 34(11):1675\u20131699. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.023","journal-title":"Cell Metab"},{"issue":"7","key":"11084_CR18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/gutjnl-2023-330826","volume":"73","author":"L Bu","year":"2024","unstructured":"Bu L, Zhang Z, Chen J et al (2024) High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT. Gut 73(7):1156\u20131168. https:\/\/doi.org\/10.1136\/gutjnl-2023-330826","journal-title":"Gut"},{"issue":"15","key":"11084_CR19","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.7150\/ijbs.64046","volume":"17","author":"M Qu","year":"2021","unstructured":"Qu M, Zhou X, Wang X et al (2021) Lipid-induced S-palmitoylation as a vital regulator of cell signaling and disease development. Int J Biol Sci 17(15):4223\u20134237. https:\/\/doi.org\/10.7150\/ijbs.64046","journal-title":"Int J Biol Sci"},{"key":"11084_CR20","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846666","author":"PJ Ko","year":"2018","unstructured":"Ko PJ, Dixon SJ (2018) Protein palmitoylation and cancer. EMBO Rep. https:\/\/doi.org\/10.15252\/embr.201846666","journal-title":"EMBO Rep"},{"key":"11084_CR21","doi-asserted-by":"publisher","unstructured":"Shuang Shang J, Liu F Hua (2022) Protein acylation: mechanisms, biological functions and therapeutic targets. Signal Transduct Target Ther 7(1). https:\/\/doi.org\/10.1038\/s41392-022-01245-y","DOI":"10.1038\/s41392-022-01245-y"},{"key":"11084_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12035","author":"Z Pei","year":"2016","unstructured":"Pei Z, Xiao Y, Meng J et al (2016) Cardiac sodium channel palmitoylation regulates channel availability and myocyte excitability with implications for arrhythmia generation. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms12035","journal-title":"Nat Commun"},{"key":"11084_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-777","author":"J Zheng","year":"2013","unstructured":"Zheng J, Liu L, Wang J (2013) Urinary proteomic and non-prefractionation quantitative phosphoproteomic analysis during pregnancy and non-pregnancy. BMC Genomics. https:\/\/doi.org\/10.1186\/1471-2164-14-777","journal-title":"BMC Genomics"},{"key":"11084_CR24","doi-asserted-by":"publisher","unstructured":"Rujun Kang J, Wan P, Arstikaitis et al (2008) Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 456(7224). https:\/\/doi.org\/10.1038\/nature07605","DOI":"10.1038\/nature07605"},{"key":"11084_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26180-4","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Li X, Yang F et al (2021) DHHC9-mediated GLUT1 s-palmitoylation promotes glioblastoma glycolysis and tumorigenesis. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-26180-4","journal-title":"Nat Commun"},{"key":"11084_CR26","doi-asserted-by":"publisher","unstructured":"Feng Tang C, Yang F-P, Li et al (2022) Palmitoyl transferases act as potential regulators of tumor-infiltrating immune cells and glioma progression. Mol Ther Nucleic Acids 28(0). https:\/\/doi.org\/10.1016\/j.omtn.2022.04.030","DOI":"10.1016\/j.omtn.2022.04.030"},{"key":"11084_CR27","doi-asserted-by":"publisher","unstructured":"Feng Tang Z, Liu X, Chen et al (2022) Current knowledge of protein palmitoylation in gliomas. Mol Biol Rep 49(11). https:\/\/doi.org\/10.1007\/s11033-022-07809-z","DOI":"10.1007\/s11033-022-07809-z"},{"key":"11084_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/jci165510","author":"J-G Ren","year":"2023","unstructured":"Ren J-G, Xing B, Lv K (2023) RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. J Clin Invest. https:\/\/doi.org\/10.1172\/jci165510","journal-title":"J Clin Invest"},{"key":"11084_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49105-3","author":"H Zhang","year":"2024","unstructured":"Zhang H, Sun Y, Wang Zhaokai et al (2024) ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-024-49105-3","journal-title":"Nat Commun"},{"key":"11084_CR30","doi-asserted-by":"publisher","unstructured":"Yang Y, Hsu J-M, Linlin Sun, et al (2018) Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res 29(1). https:\/\/doi.org\/10.1038\/s41422-018-0124-5","DOI":"10.1038\/s41422-018-0124-5"},{"key":"11084_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42476-z","author":"M Gu","year":"2023","unstructured":"Gu M, Jiang H, Tan M (2023) Palmitoyltransferase DHHC9 and acyl protein thioesterase APT1 modulate renal fibrosis through regulating \u03b2-catenin palmitoylation. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-42476-z","journal-title":"Nat Commun"},{"key":"11084_CR32","doi-asserted-by":"publisher","unstructured":"Binhui Zhou Q, Hao Y, Liang et al (2022) Protein palmitoylation in cancer: molecular functions and therapeutic potential. Mol Oncol 17(1). https:\/\/doi.org\/10.1002\/1878-0261.13308","DOI":"10.1002\/1878-0261.13308"},{"key":"11084_CR33","doi-asserted-by":"publisher","unstructured":"Vito W, Rebecca MC, Nicastri C, Fennelly et al (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov 9(2). https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0706","DOI":"10.1158\/2159-8290.cd-18-0706"},{"key":"11084_CR34","doi-asserted-by":"publisher","unstructured":"Jialei Weng S, Liu Q, Zhou et al (2023) Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. J Immunother Cancer 11(6). https:\/\/doi.org\/10.1136\/jitc-2022-006655","DOI":"10.1136\/jitc-2022-006655"},{"key":"11084_CR35","doi-asserted-by":"publisher","unstructured":"Cho S, Dawson PE, Dawson G (2000) Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells. J Neurosci Res 62(2). https:\/\/doi.org\/10.1002\/1097-4547(20001015)62:2%3C234::aid-jnr8%3E3.0.co;2-8","DOI":"10.1002\/1097-4547(20001015)62:2%3C234::aid-jnr8%3E3.0.co;2-8"},{"key":"11084_CR36","doi-asserted-by":"publisher","unstructured":"Huang T, Chen Y, Zhao Q et al (2025) Dual regulation of sprouty 4 palmitoylation by ZDHHC7 and Palmitoyl-Protein thioesterase 1: A potential therapeutic strategy for Cisplatin-Resistant osteosarcoma. Res (Wash D C) 8(0). https:\/\/doi.org\/10.34133\/research.0708","DOI":"10.34133\/research.0708"},{"issue":"3","key":"11084_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15548627.2021.1988357","volume":"18","author":"S Brun","year":"2022","unstructured":"Brun S, Bestion E, Raymond E et al (2022) viaGNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma modulation of lysosomal functions. Autophagy 18(3):678\u2013694. https:\/\/doi.org\/10.1080\/15548627.2021.1988357","journal-title":"Autophagy"},{"key":"11084_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci164596","author":"M Bhardwaj","year":"2023","unstructured":"Bhardwaj M, Lee JJ, Versace AM et al (2023) Lysosomal lipid peroxidation regulates tumor immunity. J Clin Invest. https:\/\/doi.org\/10.1172\/jci164596","journal-title":"J Clin Invest"},{"key":"11084_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133225","author":"G Sharma","year":"2020","unstructured":"Sharma G, Ojha R, Noguera-Ortega E et al (2020) Ppt1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133225","journal-title":"JCI Insight"},{"key":"11084_CR40","doi-asserted-by":"publisher","unstructured":"Fengfeng Zhou Y, Xue X, Yao et al (2006) CSS-Palm: palmitoylation site prediction with a clustering and scoring strategy (CSS). Bioinformatics 22(7). https:\/\/doi.org\/10.1093\/bioinformatics\/btl013","DOI":"10.1093\/bioinformatics\/btl013"},{"key":"11084_CR41","doi-asserted-by":"publisher","unstructured":"Mathieu Blanc, Fabrice PA, David F, Gisou, van der Goot (2019) SwissPalm 2: Protein S-Palmitoylation Database. Methods Mol Biol, 2009(0). https:\/\/doi.org\/10.1007\/978-1-4939-9532-5_16","DOI":"10.1007\/978-1-4939-9532-5_16"},{"issue":"1","key":"11084_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A et al (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17(1):54. https:\/\/doi.org\/10.1186\/s13045-024-01581-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11084_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","volume":"33","author":"H Lv","year":"2021","unstructured":"Lv H, Lv G, Chen C et al (2021) NAD metabolism maintains inducible PD-L1 expression to drive tumor immune evasion. Cell Metabol 33(1):110\u2013127e115. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.021","journal-title":"Cell Metabol"},{"key":"11084_CR44","doi-asserted-by":"publisher","unstructured":"Yang Gao NT, Nihira X, Bu et al (2020) Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol 22(9). https:\/\/doi.org\/10.1038\/s41556-020-0562-4","DOI":"10.1038\/s41556-020-0562-4"},{"issue":"1","key":"11084_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L (2021) Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 14(1):10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5","journal-title":"J Hematol Oncol"},{"key":"11084_CR46","doi-asserted-by":"publisher","unstructured":"Shi Y-Y, Gang F, Tan R et al (2024) Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates. Cell Death Dis 15(9). https:\/\/doi.org\/10.1038\/s41419-024-07073-y","DOI":"10.1038\/s41419-024-07073-y"},{"key":"11084_CR47","doi-asserted-by":"publisher","unstructured":"Zhiqing Lin K, Huang H, Guo et al (2023) Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomed Pharmacother 161(0). https:\/\/doi.org\/10.1016\/j.biopha.2023.114567","DOI":"10.1016\/j.biopha.2023.114567"},{"key":"11084_CR48","doi-asserted-by":"publisher","unstructured":"Qun Wang J, Wang D Yu, et al (2024) Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med 5(2). https:\/\/doi.org\/10.1016\/j.xcrm.2023.101357","DOI":"10.1016\/j.xcrm.2023.101357"},{"key":"11084_CR49","doi-asserted-by":"publisher","first-page":"1237964","DOI":"10.3389\/fimmu.2023.1237964","volume":"14","author":"YY Shi","year":"2023","unstructured":"Shi YY, Dong DR, Fan G et al (2023) A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells. Front Immunol 14:1237964. https:\/\/doi.org\/10.3389\/fimmu.2023.1237964","journal-title":"Front Immunol"},{"issue":"3","key":"11084_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK (2020) TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 20(3):173\u2013185. https:\/\/doi.org\/10.1038\/s41577-019-0224-6","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"11084_CR51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur MW, Nguyen TH, Coxe MA (2019) PTPN2 regulates the generation of exhausted CD8 T cell subpopulations and restrains tumor immunity. Nat Immunol 20(10):1335\u20131347. https:\/\/doi.org\/10.1038\/s41590-019-0480-4","journal-title":"Nat Immunol"},{"key":"11084_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","volume":"510","author":"S Kandel","year":"2021","unstructured":"Kandel S, Adhikary P, Li G et al (2021) The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett 510:67\u201378. https:\/\/doi.org\/10.1016\/j.canlet.2021.04.011","journal-title":"Cancer Lett"},{"key":"11084_CR53","doi-asserted-by":"publisher","unstructured":"Sashi Kandel P, Adhikary G, Li et al (2021) The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett 510(0). https:\/\/doi.org\/10.1016\/j.canlet.2021.04.011","DOI":"10.1016\/j.canlet.2021.04.011"},{"key":"11084_CR54","doi-asserted-by":"publisher","unstructured":"Ding S, Zhang T, Lei Y (2024) The role of TIM3(+) NK and TIM3(-) NK cells in the immune pathogenesis of severe aplastic anemia. J Transl Intern Med 105. https:\/\/doi.org\/10.2478\/jtim-2023-0104","DOI":"10.2478\/jtim-2023-0104"},{"key":"11084_CR55","doi-asserted-by":"publisher","unstructured":"Karen O, Dixon M, Tabaka, Markus A, Schramm et al (2021) TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595. https:\/\/doi.org\/10.1038\/s41586-021-03626-9","DOI":"10.1038\/s41586-021-03626-9"},{"key":"11084_CR56","doi-asserted-by":"publisher","unstructured":"Nannan Pang X, Alimu R, Chen et al (2021) Activated Galectin-9\/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J 35(7). https:\/\/doi.org\/10.1096\/fj.202100013R","DOI":"10.1096\/fj.202100013R"},{"key":"11084_CR57","doi-asserted-by":"publisher","unstructured":"Shin F, Ngiow, Michele WL, Teng, Mark J, Smyth (2011) Prospects for TIM3-Targeted antitumor immunotherapy. Cancer Res 71(21). https:\/\/doi.org\/10.1158\/0008-5472.can-11-1487","DOI":"10.1158\/0008-5472.can-11-1487"},{"issue":"1","key":"11084_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2","journal-title":"Mol Cancer"},{"key":"11084_CR59","doi-asserted-by":"publisher","unstructured":"Matthew D, Hellmann N, Bivi B, Calderon et al (2021) Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors. Clin Cancer Res 27(10). https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-3716","DOI":"10.1158\/1078-0432.ccr-20-3716"},{"key":"11084_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp7302","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Ren C, Xiao R et al (2024) Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.adp7302","journal-title":"Sci Immunol"},{"issue":"17","key":"11084_CR61","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1016\/j.cell.2024.06.012","volume":"187","author":"J Yu","year":"2024","unstructured":"Yu J, Yan Y, Li S et al (2024) Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell 187(17):4713\u20134732e4719. https:\/\/doi.org\/10.1016\/j.cell.2024.06.012","journal-title":"Cell"},{"issue":"8","key":"11084_CR62","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.ccr-23-1079","volume":"30","author":"SB Gitto","year":"2024","unstructured":"Gitto SB, Whicker M, Davies G et al (2024) A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression. Clin Cancer Res 30(8):1567\u20131581. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-1079","journal-title":"Clin Cancer Res"},{"issue":"7","key":"11084_CR63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41423-023-01019-8","volume":"20","author":"MC Pulanco","year":"2023","unstructured":"Pulanco MC, Madsen AT, Tanwar A et al (2023) Recent advancements in the B7\/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cell Mol Immunol 20(7):694\u2013713. https:\/\/doi.org\/10.1038\/s41423-023-01019-8","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"11084_CR64","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/2159-8290.cd-20-0402","volume":"10","author":"X Song","year":"2020","unstructured":"Song X, Zhou Z, Li H et al (2020) Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov 10(12):1872\u20131893. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0402","journal-title":"Cancer Discov"},{"issue":"12","key":"11084_CR65","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1038\/s41419-017-0015-6","volume":"8","author":"N Xie","year":"2017","unstructured":"Xie N, Cai JB, Zhang L et al (2017) Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death Dis 8(12):3205. https:\/\/doi.org\/10.1038\/s41419-017-0015-6","journal-title":"Cell Death Dis"},{"key":"11084_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12935-018-0597-9","volume":"18","author":"L Wang","year":"2018","unstructured":"Wang L, Yang C, Liu XB et al (2018) B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. Cancer Cell Int 18:100. https:\/\/doi.org\/10.1186\/s12935-018-0597-9","journal-title":"Cancer Cell Int"},{"key":"11084_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humpath.2021.04.003","volume":"113","author":"N Niu","year":"2021","unstructured":"Niu N, Shen W, Zhong Y (2021) Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20\u201327. https:\/\/doi.org\/10.1016\/j.humpath.2021.04.003","journal-title":"Hum Pathol"},{"issue":"6","key":"11084_CR68","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.ccr-22-2630","volume":"29","author":"K Kinneer","year":"2023","unstructured":"Kinneer K, Wortmann P, Cooper ZA et al (2023) Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305. Clin Cancer Res 29(6):1086\u20131101. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-2630","journal-title":"Clin Cancer Res"},{"issue":"9","key":"11084_CR69","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.mct-22-0786","volume":"22","author":"D Toader","year":"2023","unstructured":"Toader D, Fessler SP, Collins SD et al (2023) Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther 22(9):999\u20131012. https:\/\/doi.org\/10.1158\/1535-7163.mct-22-0786","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"11084_CR70","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1038\/s41467-025-58552-5","volume":"16","author":"Y Yan","year":"2025","unstructured":"Yan Y, Yu J, Wang W et al (2025) Palmitoylation prevents B7-H4 lysosomal degradation sustaining tumor immune evasion. Nat Commun 16(1):4254. https:\/\/doi.org\/10.1038\/s41467-025-58552-5","journal-title":"Nat Commun"},{"issue":"3","key":"11084_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/cmi.2008.21","volume":"5","author":"QJ Liu","year":"2008","unstructured":"Liu QJ, Gao B (2008) Manipulation of MHC-I\/TCR interaction for immune therapy. Cell Mol Immunol 5(3):171\u2013182. https:\/\/doi.org\/10.1038\/cmi.2008.21","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"11084_CR72","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R et al (2023) Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer 22(1):194. https:\/\/doi.org\/10.1186\/s12943-023-01899-4","journal-title":"Mol Cancer"},{"issue":"12","key":"11084_CR73","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/2326-6066.cir-23-0139","volume":"11","author":"DY Torrejon","year":"2023","unstructured":"Torrejon DY, Galvez M, Abril-Rodriguez G et al (2023) Antitumor immune responses in B2M-deficient cancers. Cancer Immunol Res 11(12):1642\u20131655. https:\/\/doi.org\/10.1158\/2326-6066.cir-23-0139","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"11084_CR74","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL et al (2019) An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36(4):385\u2013401e388. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.008","journal-title":"Cancer Cell"},{"issue":"19","key":"11084_CR75","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/0008-5472.can-17-3714","volume":"78","author":"S Luoto","year":"2018","unstructured":"Luoto S, Hermelo I, Vuorinen EM et al (2018) Computational characterization of suppressive immune microenvironments in glioblastoma. Cancer Res 78(19):5574\u20135585. https:\/\/doi.org\/10.1158\/0008-5472.can-17-3714","journal-title":"Cancer Res"},{"issue":"18","key":"11084_CR76","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, Lu Q, Zhou H et al (2023) A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186(18):3903\u20133920e3921. https:\/\/doi.org\/10.1016\/j.cell.2023.07.016","journal-title":"Cell"},{"issue":"1","key":"11084_CR77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41420-024-02184-z","volume":"10","author":"E Cuy\u00e0s","year":"2024","unstructured":"Cuy\u00e0s E, Pedarra S, Verdura S et al (2024) Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity. Cell Death Discov 10(1):417. https:\/\/doi.org\/10.1038\/s41420-024-02184-z","journal-title":"Cell Death Discov"},{"issue":"6","key":"11084_CR78","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/0008-5472.can-23-0966","volume":"84","author":"J Huang","year":"2024","unstructured":"Huang J, Tsang WY, Fang XN et al (2024) FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma. Cancer Res 84(6):855\u2013871. https:\/\/doi.org\/10.1158\/0008-5472.can-23-0966","journal-title":"Cancer Res"},{"key":"11084_CR79","doi-asserted-by":"publisher","unstructured":"Sansom DM, Manzotti CN, Zheng Y (2003) What\u2019s the difference between CD80 and CD86? Trends in immunology. 24(6):314\u2013319. https:\/\/doi.org\/10.1016\/s1471-4906(03)00111-x","DOI":"10.1016\/s1471-4906(03)00111-x"},{"issue":"2","key":"11084_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","volume":"57","author":"KP Burke","year":"2024","unstructured":"Burke KP, Chaudhri A, Freeman GJ et al (2024) The B7:CD28 family and friends: unraveling coinhibitory interactions. Immunity 57(2):223\u2013244. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.013","journal-title":"Immunity"},{"key":"11084_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00411","volume":"6","author":"S Ville","year":"2015","unstructured":"Ville S, Poirier N, Blancho G et al (2015) Co-stimulatory blockade of the CD28\/CD80-86\/CTLA-4 balance in transplantation: impact on memory T cells? Front Immunol 6:411. https:\/\/doi.org\/10.3389\/fimmu.2015.00411","journal-title":"Front Immunol"},{"key":"11084_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/jci148546","author":"M Corrado","year":"2022","unstructured":"Corrado M, Pearce EL (2022) Targeting memory T cell metabolism to improve immunity. J Clin Invest. https:\/\/doi.org\/10.1172\/jci148546","journal-title":"J Clin Invest"},{"issue":"1","key":"11084_CR83","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41467-023-36430-2","volume":"14","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Hu J, Kong L et al (2023) FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 14(1):735. https:\/\/doi.org\/10.1038\/s41467-023-36430-2","journal-title":"Nat Commun"},{"issue":"1","key":"11084_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20(1):44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y","journal-title":"Cell Commun Signal"},{"issue":"6","key":"11084_CR85","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41401-024-01248-1","volume":"45","author":"B Lu","year":"2024","unstructured":"Lu B, Sun YY, Chen BY et al (2024) zDHHC20-driven S-palmitoylation of CD80 is required for its costimulatory function. Acta Pharmacol Sin 45(6):1214\u20131223. https:\/\/doi.org\/10.1038\/s41401-024-01248-1","journal-title":"Acta Pharmacol Sin"},{"issue":"19","key":"11084_CR86","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.ccr-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G (2011) The two faces of interferon-\u03b3 in cancer. Clin Cancer Res 17(19):6118\u20136124. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-0482","journal-title":"Clin Cancer Res"},{"issue":"3","key":"11084_CR87","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA (2022) Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22(3):158\u2013172. https:\/\/doi.org\/10.1038\/s41577-021-00566-3","journal-title":"Nat Rev Immunol"},{"key":"11084_CR88","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou F (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28:239\u2013260. https:\/\/doi.org\/10.1080\/08830180902978120","journal-title":"Int Rev Immunol"},{"key":"11084_CR89","doi-asserted-by":"publisher","unstructured":"Tobias Bald MF, Krummel, Mark J, Smyth et al (2020) The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 21(8). https:\/\/doi.org\/10.1038\/s41590-020-0728-z","DOI":"10.1038\/s41590-020-0728-z"},{"key":"11084_CR90","doi-asserted-by":"publisher","unstructured":"Jianjun Gao LZ, Shi H, Zhao et al (2016) Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. Cell 167(2). https:\/\/doi.org\/10.1016\/j.cell.2016.08.069","DOI":"10.1016\/j.cell.2016.08.069"},{"issue":"7","key":"11084_CR91","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.cd-20-1571","volume":"11","author":"W Du","year":"2021","unstructured":"Du W, Hua F, Li X et al (2021) Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation. Cancer Discov 11(7):1826\u20131843. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1571","journal-title":"Cancer Discov"},{"issue":"6121","key":"11084_CR92","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F et al (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type i interferon pathway. Science 339(6121):786\u2013791. https:\/\/doi.org\/10.1126\/science.1232458","journal-title":"Science"},{"issue":"12","key":"11084_CR93","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A (2022) The cGAS-STING pathway and cancer. Nat Cancer 3(12):1452\u20131463. https:\/\/doi.org\/10.1038\/s43018-022-00468-w","journal-title":"Nat Cancer"},{"issue":"1","key":"11084_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.cd-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF (2020) The cytosolic DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov 10(1):26\u201339. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0761","journal-title":"Cancer Discov"},{"issue":"2","key":"11084_CR95","first-page":"179","volume":"40","author":"Y Wei","year":"2024","unstructured":"Wei Y, Liu J, Li Y et al (2024) Advances in post-translational modifications of cGAS in innate immunity. Chin J Cell Mol Immunol 40(2):179\u2013185","journal-title":"Chin J Cell Mol Immunol"},{"issue":"19","key":"11084_CR96","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1016\/j.molcel.2023.09.007","volume":"83","author":"Y Fan","year":"2023","unstructured":"Fan Y, Gao Y, Nie L et al (2023) Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy. Mol Cell 83(19):3520\u20133532e3527. https:\/\/doi.org\/10.1016\/j.molcel.2023.09.007","journal-title":"Mol Cell"},{"issue":"16","key":"11084_CR97","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1089\/ars.2021.0167","volume":"35","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kontodimas K, Bosmann M (2021) The MAVS immune recognition pathway in viral infection and sepsis. Antioxid Redox Signal 35(16):1376\u20131392. https:\/\/doi.org\/10.1089\/ars.2021.0167","journal-title":"Antioxid Redox Signal"},{"key":"11084_CR98","doi-asserted-by":"publisher","unstructured":"Boga JA, de O\u00f1a M, Melon S et al (2013) MAVS: a new weapon in the fight against viral infections. Recent patents on endocrine, metabolic & immune drug discovery. 7(2):115\u2013119. https:\/\/doi.org\/10.2174\/1872214811307020004","DOI":"10.2174\/1872214811307020004"},{"key":"11084_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104610","volume":"207","author":"X Wang","year":"2025","unstructured":"Wang X, Wang Q, Zheng C et al (2025) MAVS: the next STING in cancers and other diseases. Crit Rev Oncol Hematol 207:104610. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104610","journal-title":"Crit Rev Oncol Hematol"},{"key":"11084_CR100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2017.12.002","volume":"50","author":"B Liu","year":"2018","unstructured":"Liu B, Gao C (2018) Regulation of MAVS activation through post-translational modifications. Curr Opin Immunol 50:75\u201381. https:\/\/doi.org\/10.1016\/j.coi.2017.12.002","journal-title":"Curr Opin Immunol"},{"issue":"23","key":"11084_CR101","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1016\/j.molcel.2023.10.043","volume":"83","author":"G Zhang","year":"2023","unstructured":"Zhang G, Jiang P, Tang W et al (2023) CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. Mol Cell 83(23):4370\u20134385e4379. https:\/\/doi.org\/10.1016\/j.molcel.2023.10.043","journal-title":"Mol Cell"},{"key":"11084_CR102","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1146\/annurev-biochem-062917-011852","volume":"87","author":"MS Brown","year":"2018","unstructured":"Brown MS, Radhakrishnan A, Goldstein JL (2018) Retrospective on cholesterol homeostasis: the central role of Scap. Annu Rev Biochem 87:783\u2013807. https:\/\/doi.org\/10.1146\/annurev-biochem-062917-011852","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"11084_CR103","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.immuni.2018.08.021","volume":"49","author":"C Guo","year":"2018","unstructured":"Guo C, Chi Z, Jiang D et al (2018) Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 49(5):842\u2013856e847. https:\/\/doi.org\/10.1016\/j.immuni.2018.08.021","journal-title":"Immunity"},{"issue":"6","key":"11084_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112586","volume":"42","author":"X Fei","year":"2023","unstructured":"Fei X, Huang J, Li F et al (2023) The scap-SREBP1-S1P\/S2P lipogenesis signal orchestrates the homeostasis and spatiotemporal activation of NF-\u03baB. Cell Rep 42(6):112586. https:\/\/doi.org\/10.1016\/j.celrep.2023.112586","journal-title":"Cell Rep"},{"issue":"6","key":"11084_CR105","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2174\/1568026618666180523104541","volume":"18","author":"X Cheng","year":"2018","unstructured":"Cheng X, Li J, Guo D (2018) SCAP\/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy. Curr Top Med Chem 18(6):484\u2013493. https:\/\/doi.org\/10.2174\/1568026618666180523104541","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"11084_CR106","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2015.09.021","volume":"28","author":"C Cheng","year":"2015","unstructured":"Cheng C, Ru P, Geng F et al (2015) Glucose-mediated N-glycosylation of SCAP is essential for SREBP-1 activation and tumor growth. Cancer Cell 28(5):569\u2013581. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.021","journal-title":"Cancer Cell"},{"issue":"11","key":"11084_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114962","volume":"43","author":"M Wu","year":"2024","unstructured":"Wu M, Zhou X, Zhou X et al (2024) ZDHHC3-mediated SCAP s-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. Cell Rep 43(11):114962. https:\/\/doi.org\/10.1016\/j.celrep.2024.114962","journal-title":"Cell Rep"},{"issue":"1","key":"11084_CR108","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1039\/d0cb00157k","volume":"2","author":"H Yao","year":"2021","unstructured":"Yao H, Li C, He F (2021) A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC Chem Biol 2(1):192\u2013205. https:\/\/doi.org\/10.1039\/d0cb00157k","journal-title":"RSC Chem Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11084-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:04:50Z","timestamp":1766898290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11084-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11084"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11084-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"991"}}